Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for renal safety in heart transplant patients
NCT00097968Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2004
- Primary completion
- Apr 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of everolimus in graft rejection, cardiac allograft vasculopathy (CAV), sponsored by Novartis. Started Aug 2004; status: completed.
02
Drugs
everolimus
03
Conditions
graft rejectioncardiac allograft vasculopathy (CAV)
Beyond the preview
Go deeper on NCT00097968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00097968.